Announces open enrollment of highest dose cohort after safety review
LOS ALTOS, CA, February 19, 2016 – Retrotope announced today the successful completion of the first dose cohort and the opening of patient enrollment for the highest dose cohort in its ongoing 28-day study of orally dosed RT001 in Friedreich’s ataxia (FA) patients. RT001 was well tolerated and no serious adverse events or dose limiting toxicities were observed.
Read the entire Press Release HERE
